Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
Copyright © 2020. Published by Elsevier Ltd..
BACKGROUND: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.
METHODS: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million.
FINDINGS: We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive.
INTERPRETATION: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response.
FUNDING: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
| Errataetall: |
CommentIn: J Infect. 2021 Nov;83(5):607-635. - PMID 34433071 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
The Journal of infection - 81(2020), 6 vom: 15. Dez., Seite 931-936 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wells, Philippa M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.01.2021 Date Revised 19.09.2023 published: Print-Electronic CommentIn: J Infect. 2021 Nov;83(5):607-635. - PMID 34433071 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.10.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316380687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316380687 | ||
| 003 | DE-627 | ||
| 005 | 20231225160945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.10.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316380687 | ||
| 035 | |a (NLM)33068628 | ||
| 035 | |a (PII)S0163-4453(20)30653-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wells, Philippa M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.01.2021 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2021 Nov;83(5):607-635. - PMID 34433071 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms | ||
| 520 | |a METHODS: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million | ||
| 520 | |a FINDINGS: We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive | ||
| 520 | |a INTERPRETATION: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response | ||
| 520 | |a FUNDING: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anosmia | |
| 650 | 4 | |a Antibody | |
| 650 | 4 | |a Asymptomatic | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunity | |
| 650 | 4 | |a Population | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Seropoprevalence | |
| 650 | 4 | |a UK | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike glycoprotein, SARS-CoV |2 NLM | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 700 | 1 | |a Couvreur, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Nunez, Rocio Martinez |e verfasserin |4 aut | |
| 700 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Acors, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Kouphou, Neophytos |e verfasserin |4 aut | |
| 700 | 1 | |a Neil, Stuart J D |e verfasserin |4 aut | |
| 700 | 1 | |a Tedder, Richard S |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, Pedro M |e verfasserin |4 aut | |
| 700 | 1 | |a Poulton, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Lista, Maria Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Dickenson, Ruth E |e verfasserin |4 aut | |
| 700 | 1 | |a Sertkaya, Helin |e verfasserin |4 aut | |
| 700 | 1 | |a Maguire, Thomas J A |e verfasserin |4 aut | |
| 700 | 1 | |a Scourfield, Edward J |e verfasserin |4 aut | |
| 700 | 1 | |a Bowyer, Ruth C E |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a O'Byrne, Aoife |e verfasserin |4 aut | |
| 700 | 1 | |a Steel, Kathryn J A |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmings, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Rosadas, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a McClure, Myra O |e verfasserin |4 aut | |
| 700 | 1 | |a Capedevilla-Pujol, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Ourselin, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Malim, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Spector, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Steves, Claire J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 81(2020), 6 vom: 15. Dez., Seite 931-936 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2020 |g number:6 |g day:15 |g month:12 |g pages:931-936 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.10.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2020 |e 6 |b 15 |c 12 |h 931-936 | ||